Patents by Inventor Robert A. Zambon

Robert A. Zambon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cancellous bone product including viable osteogenic cells
    Patent number: 11865227
    Abstract: A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least one loosening agent, such as collagenase or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying out their osteogenic function and to provide for an increased rate of bone formation. Such implant also may include demineralized bone, such as demineralized cortical bone, which enhances the bone regenerative capacity of the cancellous bone.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: January 9, 2024
    Assignee: NuVasive, Inc.
    Inventors: Michelle LeRoux Williams, Charles Randal Mills, Rodney Monroy, Robert A. Zambon, Dayna Buskirk, Earl Fender
  • Cancellous Bone Product Including Viable Osteogenic Cells
    Publication number: 20210128784
    Abstract: A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least one loosening agent, such as collagenase or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying out their osteogenic function and to provide for an increased rate of bone formation. Such implant also may include demineralized bone, such as demineralized cortical bone, which enhances the bone regenerative capacity of the cancellous bone.
    Type: Application
    Filed: December 17, 2020
    Publication date: May 6, 2021
    Inventors: Michelle LeRoux Williams, Charles Randal Mills, Rodney Monroy, Robert A. Zambon, Dayna Buskirk, Earl Fender
  • Cancellous bone product including viable osteogenic cells
    Patent number: 10898611
    Abstract: A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least one loosening agent, such as collagenase or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying out their osteogenic function and to provide for an increased rate of bone formation. Such implant also may include demineralized bone, such as demineralized cortical bone, which enhances the bone regenerative capacity of the cancellous bone.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: January 26, 2021
    Assignee: NuVasive, Inc.
    Inventors: Michelle LeRoux Williams, Charles Randal Mills, Rodney Monroy, Robert A. Zambon, Dayna Buskirk, Earl Fender
  • Cancellous Bone Product Including Viable Osteogenic Cells
    Publication number: 20170281348
    Abstract: A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least one loosening agent, such as collagenase or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying out their osteogenic function and to provide for an increased rate of bone formation. Such implant also may include demineralized bone, such as demineralized cortical bone, which enhances the bone regenerative capacity of the cancellous bone.
    Type: Application
    Filed: June 14, 2017
    Publication date: October 5, 2017
    Inventors: Michelle LeRoux Williams, Charles Randal Mills, Rodney Monroy, Robert A. Zambon, Dayna Buskirk, Earl Fender
  • Cancellous bone treated with collagenase and essentially free of blood cells
    Publication number: 20080262633
    Abstract: A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least one loosening agent, such as collagenase or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying out their osteogenic function and to provide for an increased rate of bone formation. Such implant also may include demineralized bone, such as demineralized cortical bone, which enhances the bone regenerative capacity of the cancellous bone.
    Type: Application
    Filed: April 28, 2008
    Publication date: October 23, 2008
    Inventors: Michelle LeRoux Williams, Charles Randal Mills, Rodney Monroy, Robert A. Zambon, Dayna Buskirk, Earl Fender